COMPOUNDS USEFUL AS INHIBITORS OF ATR KINASE ATR

The present disclosure relates to pyrazine compounds of formula I: wherein L, n, R1, and R2 are as described in the specification. These compounds are useful as inhibitors of ATR protein kinase. The disclosure also relates to pharmaceutically acceptable compositions comprising the compounds of the d...

Full description

Saved in:
Bibliographic Details
Main Authors ODONNELL,MICHAEL M, MACCORMICK,SOMHAIRLE S, FANNING,LEV,T.D. LTD, REAPER,PHILIP MICHAEL PM, KNEGTEL,RONALD R, CLEVELAND,THOMAS T, JOSHI,PRAMOD P, SILINA,ALINA A, DURRANT,STEVEN S, HURLEY,DENNIS D, VIRANI,ANISA A, BINCH,HAYLEY H, CHARRIER,JEAN-DAMIEN J-D, PINDER,JOANNE J, KAY,DAVID D, SHETH,URVI U, YOUNG,STEPHEN S
Format Patent
LanguageChinese
English
Published 24.08.2012
Subjects
CHEMISTRY
HETEROCYCLIC COMPOUNDS
HUMAN NECESSITIES
HYGIENE
MEDICAL OR VETERINARY SCIENCE
METALLURGY
ORGANIC CHEMISTRY
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS
Online AccessGet full text

Cover

More Information
Summary:The present disclosure relates to pyrazine compounds of formula I: wherein L, n, R1, and R2 are as described in the specification. These compounds are useful as inhibitors of ATR protein kinase. The disclosure also relates to pharmaceutically acceptable compositions comprising the compounds of the disclosure; methods of treating of various diseases, disorders, and conditions using the compounds of the disclosure; processes for preparing the compounds of the disclosure; intermediates for the preparation of the compounds of the disclosure; and methods of using the compounds in in vitro applications, such as the study of kinases in biological and pathological phenomena; the study of intracellular signal transduction pathways mediated by such kinases; and the comparative evaluation of new kinase inhibitors.
Bibliography:Application Number: HK20120102078